{"id":"doi:10.1007/s11154-021-09699-1","kind":"review","title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","authors":["Manoj Kumar Mahapatra","Muthukumar Karuppasamy","Biswa Mohan Sahoo"],"author_count":3,"year":2022,"published":"2022-01-07","venue":"Reviews in Endocrine and Metabolic Disorders","cited_by":166,"doi":"10.1007/s11154-021-09699-1","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s11154-021-09699-1","archive_url":"https://space-kitty.com/papers/doi:10.1007/s11154-021-09699-1","updated":null,"pmid":"34993760","pmcid":null,"openalex_id":"W4205983920","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11154-021-09699-1.pdf","abstract":null,"abstract_license":null,"license":null,"is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Diabetes Treatment and Management"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}